Share on StockTwits

Shares of Gilead Sciences (NASDAQ:GILD) were the target of some unusual options trading activity on Friday. Stock investors bought 51,596 call options on the company, AnalystRatings.Net reports. This represents an increase of 114% compared to the average daily volume of 24,080 call options.

In other Gilead Sciences news, EVP Paul Rutherford Carter sold 16,728 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $86.45, for a total value of $1,446,135.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Nomura raised their price target on shares of Gilead Sciences from $130.00 to $141.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a research note on Monday, June 30th. They now have a $75.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, May 29th. Two research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $96.95.

Gilead Sciences (NASDAQ:GILD) traded up 4.84% on Friday, hitting $89.1899. The stock had a trading volume of 13,082,547 shares. Gilead Sciences has a 1-year low of $55.96 and a 1-year high of $90.74. The stock’s 50-day moving average is $83.40 and its 200-day moving average is $78.91. The company has a market cap of $137.0 billion and a price-to-earnings ratio of 31.51.

Gilead Sciences (NASDAQ:GILD) last released its earnings data on Tuesday, April 22nd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up 97.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $6.58 EPS for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.